BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11372588)

  • 1. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
    Kivistö KT; Wang JS; Backman JT; Nyman L; Taavitsainen P; Anttila M; Neuvonen PJ
    Eur J Clin Pharmacol; 2001 Apr; 57(1):37-42. PubMed ID: 11372588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.
    Taavitsainen P; Anttila M; Nyman L; Karnani H; Salonen JS; Pelkonen O
    Pharmacol Toxicol; 2000 May; 86(5):215-21. PubMed ID: 10862503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.
    Laine K; Anttila M; Huupponen R; Mäki-Ikola O; Heinonen E
    Clin Neuropharmacol; 2000; 23(1):22-7. PubMed ID: 10682227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.
    Palovaara S; Anttila M; Nyman L; Laine K
    Eur J Clin Pharmacol; 2002 Jul; 58(4):259-63. PubMed ID: 12136372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
    Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
    Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine.
    Benetton SA; Fang C; Yang YO; Alok R; Year M; Lin CC; Yeh LT
    Drug Metab Pharmacokinet; 2007 Apr; 22(2):78-87. PubMed ID: 17495414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline.
    Laine K; Anttila M; Nyman L; Wahlberg A; Bertilsson L
    Eur J Clin Pharmacol; 2001 May; 57(2):137-42. PubMed ID: 11417445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174.
    Kaukonen KM; Olkkola KT; Neuvonen PJ
    Eur J Clin Pharmacol; 1998 Feb; 53(6):445-9. PubMed ID: 9551703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline.
    Mascher HJ; Kikuta C; Millendorfer A; Schiel H; Ludwig G
    Int J Clin Pharmacol Ther; 1997 Jan; 35(1):9-13. PubMed ID: 9021435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
    Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Sep; 62(3):348-54. PubMed ID: 9333111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
    Neuvonen PJ; Kantola T; Kivistö KT
    Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.
    Damkier P; Hansen LL; Brosen K
    Br J Clin Pharmacol; 1999 Dec; 48(6):829-38. PubMed ID: 10594487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
    Varis T; Kivistö KT; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Nov; 68(5):487-94. PubMed ID: 11103751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
    Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan.
    Antila S; Honkanen T; Lehtonen L; Neuvonen PJ
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):446-9. PubMed ID: 9726699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism.
    Araki K; Yasui-Furukori N; Fukasawa T; Aoshima T; Suzuki A; Inoue Y; Tateishi T; Otani K
    Eur J Clin Pharmacol; 2004 Aug; 60(6):427-30. PubMed ID: 15232663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Itraconazole increases plasma concentrations of quinidine.
    Kaukonen KM; Olkkola KT; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Nov; 62(5):510-7. PubMed ID: 9390107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
    Karonen T; Laitila J; Niemi M; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2012 May; 68(5):681-8. PubMed ID: 22108774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole.
    Raaska K; Neuvonen PJ
    Eur J Clin Pharmacol; 1998 Apr; 54(2):167-70. PubMed ID: 9626923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.
    Raaska K; Niemi M; Neuvonen M; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2002 Oct; 72(4):362-9. PubMed ID: 12386638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.